The opportunity

Genetic profiling of tumor biopsies has revolutionized cancer care. However, many patients still don’t benefit from existing panel-based diagnostic tests.

Isabl analyzes 100% of the tumor genome and transcriptome, revealing and identifying relevant cancer-associated mutations in every single sample.

We offer more comprehensive biomarker discovery – creating opportunities for better diagnosis for all patients.


Experts in the development and clinical implementation of innovative genomic technologies.

Our team brings together leaders in cancer genomics, molecular diagnostics, oncology, and biomarker development from top-tier institutions such as Memorial Sloan Kettering, Harvard, and Weill Cornell Medicine.


Making full genome testing a reality for all cancer patients.

Proud recipients of the FDA Breakthrough Device Designation, Isabl GxT technology is the most comprehensive genomic test in cancer with complete analysis of the entire tumor genome and transcriptome.

Our journey

Memorial Sloan Kettering Cancer Center
Two Sigma Ventures
Y Combinator
Isabl Inc. spun off from Memorial Sloan Kettering Cancer Center in 2020 and has been funded by Two Sigma Ventures, Y Combinator, BoxOne Ventures, and others.